Autor según el artículo: Catassi C; Elli L; Bonaz B; Bouma G; Carroccio A; Castillejo G; Cellier C; Cristofori F; de Magistris L; Dolinsek J; Dieterich W; Francavilla R; Hadjivassiliou M; Holtmeier W; Körner U; Leffler DA; Lundin KEA; Mazzarella G; Mulder CJ; Pellegrini N; Rostami K; Sanders D; Skodje GI; Schuppan D; Ullrich R; Volta U; Williams M; Zevallos VF; Zopf Y; Fasano A
Departamento: Medicina i Cirurgia
Autor/es de la URV: Castillejo De Villasante, Gemma
Palabras clave: Non-celiac gluten sensitivity Irritable bowel syndrome Gastrointestinal symptom rating scale Double-blind placebo-controlled challenge Diagnosis irritable bowel syndrome gastrointestinal symptom rating scale double-blind placebo-controlled challenge diagnosis
Resumen: © 2015 by the authors; licensee MDPI, Basel, Switzerland. Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts’ recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally.
Áreas temáticas: Zootecnia / recursos pesqueiros Saúde coletiva Química Psicología Planejamento urbano e regional / demografia Nutrition and dietetics Nutrition & dietetics Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Food science Farmacia Engenharias iv Engenharias ii Enfermagem Educação física Economia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Ciência de alimentos Biotecnología
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 20726643
Direcció de correo del autor: gemma.castillejo@urv.cat
Fecha de alta del registro: 2024-09-07
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Nutrients. 7 (6): 4966-4977
Referencia de l'ítem segons les normes APA: Catassi C; Elli L; Bonaz B; Bouma G; Carroccio A; Castillejo G; Cellier C; Cristofori F; de Magistris L; Dolinsek J; Dieterich W; Francavilla R; Hadji (2015). Diagnosis of non-celiac gluten sensitivity (NCGS): The salerno experts’ criteria. Nutrients, 7(6), 4966-4977. DOI: 10.3390/nu7064966
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2015
Tipo de publicación: Journal Publications
Repositori URV